Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Chidiebere U. Awah"'
Autor:
Chidiebere U. Awah, Joo Sun Mun, Aloka Paragodaarachchi, Baris Boylu, Martin Nzegwu, Hiroshi Matsui, Olorunseun Ogunwobi
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Non-small cell lung cancer (NSCLC) caused more deaths in 2017 than breast cancer, prostate, and brain cancers combined. This is primarily due to their aggressive metastatic nature, leading to more fatal rates of cancer patients. Despite this conditio
Externí odkaz:
https://doaj.org/article/d0be878fbec7454e8fe5d7d025ee83e3
Publikováno v:
All Life, Vol 15, Iss 1, Pp 88-93 (2022)
Glioblastoma is the most fatal of all primary human brain tumors, with a 14-month median survival. The mainstay therapy for this tumor involves temozolomide, surgery, radiotherapy, and tumor-treating electric field. Cancer resistance to commonly avai
Externí odkaz:
https://doaj.org/article/971edc64f2c945ada4efd9545c0baf71
Autor:
Chidiebere U. Awah, Yana Glemaud, Fayola Levine, Kiseok Yang, Afrin Ansary, Fu Dong, Leonard Ash, Junfei Zhang, Olorunseun O. Ogunwobi
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Breast, lung, and colorectal cancer resistance to molecular targeted therapy is a major challenge that unfavorably impacts clinical outcomes leading to hundreds of thousands of deaths annually. In ERBB2+ cancers regardless of the tissue of origin, ma
Externí odkaz:
https://doaj.org/article/c0558a24851944ae854a1c8e6f92e72b
Publikováno v:
Frontiers in Neurology, Vol 9 (2018)
Despite advances in surgery, radiotherapy, and chemotherapy, glioblastoma (GBM) remains a malignancy with poor prognosis. The molecular profile of GBM is diverse across patients, and individual responses to therapy are highly variable. Yet, patients
Externí odkaz:
https://doaj.org/article/3dee0bb578ed44af90a3ab5dee530c6e
Autor:
Chidiebere U Awah, Yana Glemaud, Fayola Levine, Kiseok Yang, Afrin Ansary, Fu Dong, Leonard Ash, Junfei Zhang, Daniel Weiser, Olorunseun O Ogunwobi
Breast, lung, and colorectal cancer resistance to molecular targeted therapy is a major challenge and unfavorably impacts clinical outcomes, leading to hundreds of thousands of deaths yearly. In ERBB2+ cancers regardless of the tissue of origin, ERBB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7914a9feba78233ca545a6660d009f6a
https://doi.org/10.1101/2022.08.14.503914
https://doi.org/10.1101/2022.08.14.503914
Publikováno v:
Cancer Research. 83:4504-4504
Prostate cancer is the most common cancer in men and the second leading cause of cancer death among men in the United States according to the National Cancer Institute. Current treatment modalities involve prostatectomy, androgen receptor blockade an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e27fca3f6a29bf39a71b6757044e33d8
https://doi.org/10.1158/1538-7445.am2023-4504
https://doi.org/10.1158/1538-7445.am2023-4504
Autor:
Chidiebere U. Awah, Joo Sun Mun, Baris Boylu, Alooka Paragodaarachchi, Chika Ochu, Junfei Zhang, Hiroshi Mastui, Olorunseun Ogunwobi
Publikováno v:
Cancer Research. 83:1459-1459
c-MYC is a master transcription factor overexpressed in more than 70% of human cancers including breast cancers (TNBC), lung cancers, brain tumors, prostate cancers, lymphomas, pediatrics cancers, pancreatic cancers, colorectal cancers, and ovarian c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2f150a73eaee90eb417882ee614bb90
https://doi.org/10.1158/1538-7445.am2023-1459
https://doi.org/10.1158/1538-7445.am2023-1459
Autor:
Chidiebere U. Awah, Joo Sun Mun, Baris Boylu, Alooka Paragodaarachchi, Chika Ochu, Junfei Zhang, Hiroshi Matsui, Olorunseun O. Ogunwobi
Publikováno v:
Cancer Research. 83:3417-3417
Non-small cell lung cancer (NSCLC) caused more deaths in 2017 than breast cancer, prostate cancer and brain cancers combined. This is primarily due to its metastatic abilities to organs such brain, liver, bones, and adrenal glands leading to death of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56978c53b59754629a6cf45e40dc2b9f
https://doi.org/10.1158/1538-7445.am2023-3417
https://doi.org/10.1158/1538-7445.am2023-3417
Autor:
Chidiebere U. Awah, Joo Sun Mun, Baris Boylu, Alooka Paragodaarachchi, Chika Ochu, Hiroshi Matsui, Olorunseun O. Ogunwobi
Publikováno v:
Cancer Research. 83:3900-3900
Breast cancer is the most common form of cancer in women with mortality of about 58% in developing countries. HER2+ breast cancers are treated with trastuzumab in various forms in combination with chemotherapy and has been successful in targeting HER
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f4e5f9f25667c2125bb097623432138
https://doi.org/10.1158/1538-7445.am2023-3900
https://doi.org/10.1158/1538-7445.am2023-3900
Autor:
Jan Winter, Chidiebere U. Awah, Markella Zannikou, Denise M. Scholtens, Regina T. Martuscello, Edgar Gonzalez-Buendia, Li Chen, Patrick D. Hsu, Silvana Konerman, Atique Ahmed, Roger Stupp, Daniel Zhang, Dou Yu, Irina V. Balyasnikova, Louisa Warnke, Mukesh Bansal, Balázs Győrffy, Cheol Park, Kirsten Bell Burdett, Adam M. Sonabend, Meeki Lad, Aayushi Mahajan, Eric Feldstein
Publikováno v:
Oncogene
Oncogene, vol 39, iss 27
Oncogene, vol 39, iss 27
Topoisomerase II poisons are one of the most common class of chemotherapeutics used in cancer. We and others had shown that a subset of glioblastomas (GBM), the most malignant of all primary brain tumors in adults, are responsive to TOP2 poisons. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f691a3b95363dc26f76ef46b3bc89afe
http://europepmc.org/articles/PMC7646677
http://europepmc.org/articles/PMC7646677